Who is sponsoring NCT04384770?

NCT04384770 is sponsored by Jonsson Comprehensive Cancer Center.

What drugs are being tested in NCT04384770?

Interventions in NCT04384770: CT-guided Stereotactic Body Radiation Therapy, MRI-guided Stereotactic Body Radiation Therapy, Questionnaire Administration.

What condition does NCT04384770 study?

NCT04384770 studies Prostate Adenocarcinoma.

Is NCT04384770 still recruiting?

NCT04384770 is currently active, enrolled. Last updated 22 December 2025.

Last reviewed 2025-12-22 · How we verify

NCT04384770

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CT-guided Stereotactic Body Radiation Therapy and MRI-guided Stereotactic Body Radiation Therapy for Prostate Cancer, MIRAGE Study

Active, enrolled Last updated 22 December 2025

What this trial tests

trial testing CT-guided Stereotactic Body Radiation Therapy in Prostate Adenocarcinoma in 179 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

12 May 2020

Primary endpoint
1 April 2026

1 April 2027

Quick facts

Lead sponsor	Jonsson Comprehensive Cancer Center
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	179
Start date	12 May 2020
Primary completion	1 April 2026
Estimated completion	1 April 2027
Sites	1 location across United States

Drugs / interventions tested

CT-guided Stereotactic Body Radiation Therapy
MRI-guided Stereotactic Body Radiation Therapy
Questionnaire Administration

Conditions studied

Prostate Adenocarcinoma — all drugs for Prostate Adenocarcinoma →

Sponsor

Jonsson Comprehensive Cancer Center — full company profile →

Who can join

18 and older, male only, with Prostate Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase III trial studies compares CT-guided stereotactic body radiation therapy and MRI-guided stereotactic body radiation therapy (SBRT) in treating prostate cancer. Image-guided SBRT is a standard treatment for prostate cancer, which combines imaging of the cancer within the body with the delivery of therapeutic radiation doses produced on a linear accelerator machine. Imaging modalities for image-guided SBRT can be either computed tomography imaging (CT), magnetic resonance imaging (MRI), or a combination of the two. This research is being done to help determine whether there are benefits to MRI-guidance over CT-guidance in patients who are receiving the same radiation dose by SBRT to treat prostate cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial.
Kishan AU, Ma TM, Lamb JM, Casado M, et al · · 2023 · cited 218× · PMID 36633877 · DOI 10.1001/jamaoncol.2022.6558
Magnetic resonance linear accelerator technology and adaptive radiation therapy: An overview for clinicians.
Hall WA, Paulson E, Li XA, Erickson B, et al · · 2022 · cited 76× · PMID 34792808 · DOI 10.3322/caac.21707
MR-Guided Radiotherapy for Prostate Cancer.
Tocco BR, Kishan AU, Ma TM, Kerkmeijer LGW, et al · · 2020 · cited 62× · PMID 33363041 · DOI 10.3389/fonc.2020.616291
Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial.
Ma TM, Lamb JM, Casado M, Wang X, et al · · 2021 · cited 33× · PMID 33975579 · DOI 10.1186/s12885-021-08281-x
Stereotactic Magnetic Resonance-Guided Adaptive and Non-Adaptive Radiotherapy on Combination MR-Linear Accelerators: Current Practice and Future Directions.
Bryant JM, Weygand J, Keit E, Cruz-Chamorro R, et al · · 2023 · cited 24× · PMID 37046741 · DOI 10.3390/cancers15072081
Quantifying Intrafraction Motion and the Impact of Gating for Magnetic Resonance Imaging-Guided Stereotactic Radiation therapy for Prostate Cancer: Analysis of the Magnetic Resonance Imaging Arm From the MIRAGE Phase 3 Randomized Trial.
Neylon J, Ma TM, Savjani R, Low DA, et al · · 2024 · cited 20× · PMID 38160916 · DOI 10.1016/j.ijrobp.2023.12.035
Magnetic Resonance Imaging Versus Computed Tomography Guidance for Stereotactic Body Radiotherapy in Prostate Cancer: 2-year Outcomes from the MIRAGE Randomized Clinical Trial.
Kishan AU, Lamb JM, Wilhalme H, Casado M, et al · · 2025 · cited 16× · PMID 39537438 · DOI 10.1016/j.eururo.2024.10.026
Patterns of utilization and clinical adoption of 0.35 Tesla MR-guided radiation therapy in the United States - Understanding the transition to adaptive, ultra-hypofractionated treatments.
Chuong MD, Clark MA, Henke LE, Kishan AU, et al · · 2023 · cited 16× · PMID 36466748 · DOI 10.1016/j.ctro.2022.11.013

Verify or expand the search:

Other trials of CT-guided Stereotactic Body Radiation Therapy

Trials testing the same drug.

NCT07276438 — Image-Guidance and Online Adaptation With Stereotactic Body Radiation Therapy for the Treatment of Localized Prostate Ca · NA · recruiting
NCT06995053 — Computed Tomography-Guided Stereotactic Body Radiation Therapy With Intrafraction Motion Monitoring for the Treatment of · NA · recruiting

Other recruiting trials for Prostate Adenocarcinoma

Currently open trials in the same condition.

NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response · NA · recruiting
NCT07285057 — Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance · Phase 2 · recruiting
NCT06957691 — Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Pro · Phase 2 · recruiting
NCT07025369 — Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With H · Phase 2 · recruiting
NCT06967961 — Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers · NA · recruiting

Other Jonsson Comprehensive Cancer Center trials

Trials by the same sponsor.

NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT06448286 — PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glio · Phase 3 · not yet recruiting
NCT07517211 — A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, · not yet recruiting
NCT07191717 — Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Resi · Phase 2 · not yet recruiting
NCT07468903 — Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04384770 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jonsson Comprehensive Cancer Center
Last refreshed: 22 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04384770.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing